Maryland AG Files Suit Against Drug Companies for Blocking Competitors’ Production of Generic Cholesterol Lowering Drug
BALTIMORE, MD (March 18, 2008) - Maryland Attorney General Douglas F. Gansler today filed suit against Abbott Laboratories and French drug company Fournier Industrie et Sante alleging that the firms violated state and federal antitrust laws by delaying the availability of cheaper, generic versions of TriCor, a cholesterol drug which last year accounted for over one billion dollars of Abbott’s sales.
The civil complaint filed in federal court in Delaware alleges that the two drug companies conspired to prevent the marketing of less expensive generic versions of TriCor, Abbott’s brand name for fenofibrate, a drug used to reduce high levels of triglycerides and cholesterol.
The complaint alleges that Abbott and Fournier obtained patents protecting TriCor from competition by deceiving the Patent Office with incomplete and misleading data. Abbott and Fournier then brought more than 10 groundless patent infringement lawsuits against these generic companies between 2000 and 2004 to prevent them from obtaining Federal Food and Drug Administration approval to market their generic versions of Tricor. Abbott and Fournier eventually lost or dismissed all of the lawsuits.
Abbott and Fournier also made minor changes in the formulations of TriCor, not to improve it, but to prevent competing drug companies’ generic versions from qualifying under FDA rules as substitutes for the more costly TriCor. Abbott and Fournier further ensured that TriCor would not face generic competition by withdrawing earlier TriCor versions from the market before generic substitutes to these versions could be marketed. When consumers purchase generic versions of major brand name drugs, the price is often 50-80 percent less than the branded drug.
“Many Marylanders struggle to pay for the drugs that they need to preserve their health,” said Attorney General Gansler. “We cannot tolerate schemes that artificially increase the burdens on our citizens and on the State.”
Maryland’s lawsuit seeks three times the amount of overpayments made by the State and by Marylanders who purchased TriCor. Maryland was joined in this suit by Arizona, Arkansas, California, Connecticut, the District of Columbia, Florida, Iowa, Kansas, Maine, Minnesota, Missouri, Nevada, New York, Oregon, Pennsylvania, South Carolina, Washington, and West Virginia.
Source: Maryland Attorney General
Similar
- Missouri AG Nixon Sues Pharmaceutical Companies Abbott And Fournier For Illegally Blocking Generic Competition To TriCor
- Florida, 18 States Sue Abbott Laboratories for Blocking Generic Prescription Competition
- Illinois AG Madigan, 29 States Reach $58 Million Settlement With Merck
- Idaho to Receive More than $1.1 Million from Vioxx Maker Merck
- Florida AG Files $58 Million Multistate Judgment to Resolve Three-Year Investigation into Merck Pharmaceutical
Latest stories
- Iowans Should Take a Holiday from Disaster-Related Stress This Weekend
- EPA Is Not Currently Performing Indoor Air Sampling in Response to Iowa Floods
- EPA Monitors Air Quality in Cleanup from Iowa Floods
- Be Vigilant for Disaster Scam Artists
- Pfizer Announce Changes to Its Funding of Continuing Medical Education in the U.S.
- IBM Acquires Platform Solutions Technology Company
- CoverGirl, P.F. Chang's China Bistro Team up in Celebration of the Essence Music Festival
- AT&T, Cell Phones for Soldiers Surpass First-Year Goal
- Wal-Mart Commits to America's Farmers as Store Produce Aisles Go Local
- IBM, ETH Scientists Advance Supercomputing Simulations to Improve Diagnosis of Osteoporosis
Yes We Can
Yes We Can:

















